Dublin, July 24, 2025 (GLOBE NEWSWIRE) -- The "Fibroblast Growth Factors (FGFs) Global Market Report 2025" has been added to ResearchAndMarkets.com's offering.
The fibroblast growth factors (FGFs) market is poised for substantial growth, projected to expand from $0.86 billion in 2024 to $1.34 billion by 2025, at a CAGR of 11.9%. This upward trend is driven by the escalation in regenerative medicine demand, coupled with the notable use of FGFs in wound healing and cancer research. Advancements in biopharmaceuticals and increasing awareness of FGFs' therapeutic potential also contribute to this optimistic forecast.
The market trajectory is set to continue, reaching $1.34 billion by 2029, with a CAGR of 11.6% during the forecasted period. Key factors include increased personalized medicine investments, adoption of FGF-based therapies, and the rise of chronic diseases. Progress in biotechnology, coupled with strategic collaborations between pharmaceutical entities and research institutions, further reinforce this growth.
The surge in chronic disease prevalence underpins the burgeoning FGFs market. Sedentary lifestyles have correlated with rising rates of conditions such as heart disease and diabetes. In June 2024, the UK's NHS reported a notable increase in non-diabetic hyperglycemia diagnoses, highlighting the urgent need for effective therapeutics like FGFs. By supporting tissue repair and regeneration, FGFs effectively manage chronic diseases, enhance outcomes, and improve quality of life.
Leading companies prioritize innovation, focusing on engineered FGF variants that bolster therapeutic efficacy and support regenerative treatments for chronic and degenerative conditions. In October 2022, Zhittya Genesis Medicine introduced a pioneering FGF-1 therapy targeting Parkinson's disease, indicative of the novel applications in combating disease progression.
Strategic acquisitions play a pivotal role in market dynamics. In January 2022, Thermo Fisher Scientific Inc. acquired PeproTech Inc. for approximately $1.85 billion, enhancing its capabilities in cell and gene therapy through a comprehensive portfolio of recombinant proteins, including FGFs.
Major players include Merck & Co. Inc., Bristol-Myers Squibb, Thermo Fisher, Novartis AG, and others. North America emerged as the largest market region in 2024, with Asia-Pacific poised as the fastest-growing region during the forecast period. The regions covered in the FGFs report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
The FGFs market encompasses recombinant, purified, and endogenous FGFs, with applications spanning oncology, hematology, wound healing, dermatology, cardiovascular diseases, and tissue regeneration. End users notably include pharmaceutical companies, biotech firms, and research institutions.
This FGFs market report provides comprehensive insights into market size, regional shares, and competitive landscape, enabling stakeholders to navigate the evolving dynamics effectively. By offering detailed market segments, trends, and opportunities, the report equips readers to capitalize on the burgeoning growth projected within the FGFs industry.
Reasons to Purchase:
- Acquire a truly global perspective with comprehensive coverage across 15 geographies.
- Evaluate the effects of macro factors such as geopolitical tensions, pandemic recovery, inflation, and the impact of political shifts.
- Develop country and regional strategies based on localized data analysis.
- Identify promising growth segments for strategic investments.
- Utilize predictive data and market drivers to surpass competition.
- Understand customer dynamics through current market shares.
- Benchmark against key competitors effectively.
- Support your presentations with accurate data and market analysis.
- Stay updated with the latest data, complete with an Excel data sheet for in-depth analysis and extraction.
- Gain access to all report data in an easy-to-navigate Excel dashboard format.
Scope
- Product Types: Recombinant, Purified, Endogenous, Others
- Types: Palifermin, Erdafitnib, Infigratinib, Futibatinib, Others
- Applications: Oncology, Hematology, Wound Healing, Dermatology, Cardiovascular and Bone Disorders, Tissue Regeneration, Others
- End Users: Pharmaceutical Firms, Research Institutes, Biotechnology Companies, Others
Companies Featured
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- Thermo Fisher Scientific Inc.
- Novartis AG
- FUJIFILM Wako Pure Chemical Corporation
- Lonza Group AG
- Miltenyi Biotec B.V. & Co. KG
- GenScript Biotech Corporation
- 89bio Inc.
- R&D Systems Inc.
- ACROBiosystems Co. Ltd.
- Elabscience Biotechnology Inc.
- Cell Signaling Technology Inc.
- BPS Bioscience Inc.
- Proteintech Group Inc.
- Akero Therapeutics Inc.
- MedChemExpress LLC
- Defined Bioscience Inc.
- Gold Biotechnology Inc. (GoldBio)
- Nucleus Biologics LLC
- ZellBio GmbH
- Affinity Biosciences Ltd.
- GeneCards
For more information about this report visit https://www.researchandmarkets.com/r/jk3j0i
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
